Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: A retrospective study

Anesthesiology

Volumn 113, Issue 3, 2010, Pages 570-576

  Wuethrich, Patrick Y ^b   Schmitz, Shu Fang Hsu ^c   Kessler, Thomas M ^d   Thalmann, George N ^d   Studer, Urs E ^b   Stueber, Frank ^a   Burkhard, Fiona C ^d  

^a University Department of Anaesthesiology and Pain Therapy   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Inselspital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ATRACURIUM; BUPIVACAINE; FENTANYL; KETOROLAC; MORPHINE; PROSTATE SPECIFIC ANTIGEN; ROCURONIUM; THIOPENTAL;

ADULT; AGED; ANESTHESIOLOGICAL TECHNIQUES; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; EPIDURAL ANESTHESIA; GENERAL ANESTHESIA; GLEASON SCORE; HUMAN; INTRAVENOUS ANESTHESIA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; ANESTHESIA, EPIDURAL; ANESTHESIA, GENERAL; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956985315     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181e4f6ec     Document Type: Article

References (35)

1. Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ: Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: A retrospective analysis. ANESTHESIOLOGY 2008; 109:180-187
2. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI: Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? ANESTHESIOLOGY 2006; 105:660-664
3. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL: Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148:435-448
4. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE: Scandinavian Prostate Cancer Group Study No. 4: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977- 1984 (Pubitemid 40638368)
5. Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobsen SJ: Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: A retrospective analysis. Cancer 2001; 91:2302-2314
6. Burkhard FC, Studer UE: Regional lymph node staging in prostate cancer: Prognostic and therapeutic implications. Surg Oncol 2009; 18:213-218
7. Fleischmann A, Schobinger S, Markwalder R, Schumacher M, Burkhard F, Thalmann GN, Studer UE: Prognostic factors in lymph node metastases of prostatic cancer patients: The size of the metastases but not extranodal extension independently predicts survival. Histopathology 2008; 53: 468-475
8. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167:528-534
9. Neulander EZ, Greene GF, Wajsman Z: Biochemical disease- free survival in patients with a high prostate-specific antigen level (20 -100 ng/mL) and clinically localized prostate cancer after radical prostatectomy (letter). BJU Int 2003; 92:824
10. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM: Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml. correlate poorly with post-radical prostatectomy cancer morphology: Prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002; 167:103-111
11. van den Ouden D, Hop WC, Schröder FH: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998; 160:1392-1397
12. Burkhard FC, Schumacher MC, Studer UE: An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 2006; 3:454-455
13. Burkhard FC, Studer UE: The role of lymphadenectomy in prostate cancer. Urol Oncol 2004; 22:198-202; discussion 202-204
14. Dhar NB, Burkhard FC, Studer UE: Role of lymphadenectomy in clinically organ-confined prostate cancer. World J Urol 2007; 25:39-44
15. Kessler TM, Burkhard FC, Studer UE: Nerve-sparing open radical retropubic prostatectomy. Eur Urol 2007; 51:90-97
16. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE: Is pelvic lymph node dissection necessary in patients with a serum PSA <10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006; 50:272-279
17. Thurairaja R, Studer UE, Burkhard FC: Indications, extent, and benefits of pelvic lymph node dissection for patients with bladder and prostate cancer. Oncologist 2009; 14:40-51
18. Rosenbaum PR, Ruben DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55
19. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V: Principles for modeling propensity scores in medical research: A systematic literature review. Pharmacoepidemiol Drug Saf 2004; 13:841-853
20. Cole SR, Hernán MA: Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 2004; 75:45-49
21. Bar-Yosef S, Melamed R, Page GG, Shakhar G, Shakhar K, Ben-Eliyahu S: Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. ANESTHESIOLOGY 2001; 94:1066-1073
22. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G: Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999; 80:880-888
23. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, Ben-Eliyahu S: Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008; 15:2042-2052
24. Chae BK, Lee HW, Sun K, Choi YH, Kim HM: The effect of combined epidural and light general anesthesia on stress hormones in open heart surgery patients. Surg Today 1998; 28:727-731
25. O'Riain SC, Buggy DJ, Kerin MJ, Watson RW, Moriarty DC: Inhibition of the stress response to breast cancer surgery by regional anesthesia and analgesia does not affect vascular endothelial growth factor and prostaglandin E2. Anesth Analg 2005; 100:244-249
26. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42:73-78
27. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE: Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54:344-352
28. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17:1499-1507
29. Haukaas SA, Halvorsen OJ, Daehlin L, Hostmark J, Akslen LA: Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? BJU Int 2006; 97:51-55
30. Beilin B, Shavit Y, Hart J, Mordashov B, Cohn S, Notti I, Bessler H: Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 1996; 82:492-497
31. Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, Ammatuna M, Panerai AE: The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000; 90:1411-1414
32. Markovic SN, Murasko DM: Anesthesia inhibits interferoninduced natural killer cell cytotoxicity via induction of CD8+ suppressor cells. Cell Immunol 1993; 151:474-480
33. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62: 4491-4498
34. Basler JW, Piazza GA: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 2004; 171:S59 - 62; discussion S62-3
35. Lucia MS, Torkko KC: Inflammation as a target for prostate cancer chemoprevention: Pathological and laboratory rationale. J Urol 2004; 171:S30 - 4; discussion S35